Highlights & Basics
- Amphetamine and methamphetamine use disorders involve compulsive substance use despite negative consequences.
- Polysubstance use, for example with opioids, is an increasing problem, and increases mortality.
- Psychosocial interventions such as contingency management, cognitive behavioral therapy (CBT), motivational interviewing, Matrix model, and community reinforcement approach are the mainstays of treatment; no medication has yet proven effective.
- Effective management strategies incorporate a degree of long-term continuing care in addition to acute management of exacerbations.
- Evaluation and management of co-occurring psychiatric conditions is essential.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
National Institute on Drug Abuse. Methamphetamine research report: what is methamphetamine? Oct 2019 [internet publication].[Full Text]
Paulus MP, Stewart JL. Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiatry. 2020 Sep 1;77(9):959-66.[Abstract][Full Text]
Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment for stimulant use disorders: updated 2021. Treatment Improvement Protocol (TIP) series, no. 33. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1999 (updated 2021).[Abstract][Full Text]
World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].[Full Text]
Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020 Apr;34(4):337-65.[Abstract][Full Text]
Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. Expert Opin Pharmacother. 2019 Dec;20(18):2273-93.[Abstract]
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
2. Kish SJ. Pharmacologic mechanisms of crystal meth. CMAJ. 2008 Jun 17;178(13):1679-82.[Abstract][Full Text]
3. Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013 May 1;129(3):167-79.[Abstract]
4. Moszczynska A. Neurobiology and clinical manifestations of methamphetamine neurotoxicity. Psychiatr Times. 2016 Sep;33(9):16-8.[Abstract][Full Text]
5. National Institute on Drug Abuse. Methamphetamine research report: what is methamphetamine? Oct 2019 [internet publication].[Full Text]
6. Paulus MP, Stewart JL. Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiatry. 2020 Sep 1;77(9):959-66.[Abstract][Full Text]
7. United Nations Office on Drugs and Crime. World drug report 2022. Jun 2022 [internet publication].[Full Text]
8. Stoneberg DM, Shukla RK, Magness MB. Global methamphetamine trends: an evolving problem. Int Crim Just Rev. 2017;28(2):136-61.[Full Text]
9. European Monitoring Centre for Drugs and Drug Addiction. EU drug market: methamphetamine. 2022 [internet publication].[Full Text]
10. Substance Abuse and Mental Health Services Administration (SAMHSA). 2021 National Survey of Drug Use and Health (NSDUH) releases. 2021 [internet publication].[Full Text]
11. Chen T, Spiller HA, Badeti J, et al. Methamphetamine exposures reported to United States poison control centers, 2000-2019. Clin Toxicol (Phila). 2021 Aug;59(8):705-14.[Abstract]
12. Monitoring the Future. Methamphetamine: trends in last 12 months prevalence of use in 8th, 10th, and 12th grade. 2023 [internet publication].[Full Text]
13. American Society of Addiction Medicine/American Academy of Addiction Psychiatry. The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024 May-Jun;18(1S):1-56.[Full Text]
14. Centers for Disease Control and Prevention. CDC WONDERSearch: about underlying cause of death, 1999-2020. 2023 [internet publication].[Full Text]
15. Hedegaard H, Bastian BA, Trinidad JP, et al. Drugs most frequently involved in drug overdose deaths: United States, 2011-2016. Natl Vital Stat Rep. 2018 Dec;67(9):1-14.[Abstract][Full Text]
16. Winkelman TNA, Admon LK, Jennings L, et al. Evaluation of amphetamine-related hospitalizations and associated clinical outcomes and costs in the United States. JAMA Netw Open. 2018 Oct 5;1(6):e183758.[Abstract][Full Text]
17. Hedegaard H, Bastian BA, Trinidad JP, et al. Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017. Natl Vital Stat Rep. 2019 Oct;68(12):1-16.[Abstract][Full Text]
18. Kariisa M, Scholl L, Wilson N, et al. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017. MMWR Morb Mortal Wkly Rep. 2019 May 3;68(17):388-95.[Abstract][Full Text]
19. Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020 Apr;94(4):1085-133.[Abstract][Full Text]
20. Daniulaityte R, Silverstein SM, Crawford TN, et al. Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern U.S. city. Subst Use Misuse. 2020;55(11):1781-9.[Abstract][Full Text]
21. Glick SN, Klein KS, Tinsley J, et al. Increasing heroin-methamphetamine (goofball) use and related morbidity among Seattle area people who inject drugs. Am J Addict. 2021 Mar;30(2):183-91.[Abstract][Full Text]
22. Glick SN, Burt R, Kummer K, et al. Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. Drug Alcohol Depend. 2018 Jan 1;182:86-92.[Abstract][Full Text]
23. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment for stimulant use disorders: updated 2021. Treatment Improvement Protocol (TIP) series, no. 33. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1999 (updated 2021).[Abstract][Full Text]
24. Centers for Disease Control and Prevention. Annual surveillance report of drug-related risks and outcomes: United States, 2019. Nov 2019 [internet publication].[Full Text]
25. Pro G, Hayes C, Montgomery BEE, et al. Demographic and geographic shifts in the preferred route of methamphetamine administration among treatment cases in the US, 2010-2019. Drug Alcohol Depend. 2022 Aug 1;237:109535.[Abstract]
26. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2017. 2017 [internet publication].[Full Text]
27. Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011 Apr 30;186(2-3):356-61.[Abstract][Full Text]
28. Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab Brain Dis. 2014 Jun;29(2):351-7.[Abstract]
29. Zhou Y, Hu Y, Wang Q, et al. Association between white matter microstructure and cognitive function in patients with methamphetamine use disorder. Hum Brain Mapp. 2023 Feb 1;44(2):304-14.[Abstract][Full Text]
30. Hart CL, Marvin CB, Silver R, et al. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology. 2012 Feb;37(3):586-608.[Abstract][Full Text]
31. Basterfield C, Hester R, Bowden SC. A meta-analysis of the relationship between abstinence and neuropsychological functioning in methamphetamine use disorder. Neuropsychology. 2019 Jul;33(5):739-53.[Abstract]
32. Sung YH, Cho SC, Hwang J, et al. Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend. 2007 Apr 17;88(1):28-35.[Abstract]
33. Hall MG, Alhassoon OM, Stern MJ, et al. Gray matter abnormalities in cocaine versus methamphetamine-dependent patients: a neuroimaging meta-analysis. Am J Drug Alcohol Abuse. 2015;41(4):290-9.[Abstract]
34. Lyoo IK, Yoon S, Kim TS, et al. Predisposition to and effects of methamphetamine use on the adolescent brain. Mol Psychiatry. 2015 Dec;20(12):1516-24.[Abstract][Full Text]
35. Davidson C, Gow AJ, Lee TH, et al. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001 Aug;36(1):1-22.[Abstract]
36. Whitesell M, Bachand A, Peel J, et al. Familial, social, and individual factors contributing to risk for adolescent substance use. J Addict. 2013 Mar 20;2013:579310.[Abstract][Full Text]
37. Kilpatrick DG, Acierno R, Saunders B, et al. Risk factors for adolescent substance abuse and dependence: data from a national sample. J Consult Clin Psychol. 2000 Feb;68(1):19-30.[Abstract]
38. Hawkins JD, Catalano RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychol Bull. 1992 Jul;112(1):64-105.[Abstract]
39. Chen Y, Zhang J, Sun Y. The relationship between childhood abuse and depression in a sample of Chinese people who use methamphetamine. Int J Clin Health Psychol. 2019 Sep;19(3):181-18.[Abstract][Full Text]
40. Simpson JL, Grant KM, Daly PM, et al. Psychological burden and gender differences in methamphetamine-dependent individuals in treatment. J Psychoactive Drugs. 2016 Sep-Oct;48(4):261-9.[Abstract]
41. Svingen L, Dykstra RE, Simpson JL, et al. Associations between family history of substance use, childhood trauma, and age of first drug use in persons with methamphetamine dependence. J Addict Med. 2016 Jul-Aug;10(4):269-73.[Abstract]
42. Hendrickson RG, Horowitz BZ, Norton RL. "Parachuting" meth: a novel delivery method for methamphetamine and delayed-onset toxicity from "body stuffing". Clin Toxicol (Phila). 2006;44(4):379-82.[Abstract]
43. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990 Nov 21;264(19):2511-8.[Abstract]
44. O'Neil KA, Conner BT, Kendall PC. Internalizing disorders and substance use disorders in youth: comorbidity, risk, temporal order, and implications for intervention. Clin Psychol Rev. 2011 Feb;31(1):104-12.[Abstract]
45. Shadur JM, Lejuez CW. Adolescent substance use and comorbid psychopathology: emotion regulation deficits as a transdiagnostic risk factor. Curr Addict Rep. 2015 Dec 1;2(4):354-63.[Abstract][Full Text]
46. McKetin R, Kothe A, Baker AL, et al. Predicting abstinence from methamphetamine use after residential rehabilitation: findings from the Methamphetamine Treatment Evaluation Study. Drug Alcohol Rev. 2018 Jan;37(1):70-8.[Abstract]
47. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, et al; Methamphetamine Treatment Project Corporate Authors. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009 Apr;197(4):225-31.[Abstract][Full Text]
48. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Primary care-based interventions to prevent illicit drug use in children, adolescents, and young adults: US Preventive Services Task Force recommendation statement. JAMA. 2020 May 26;323(20):2060-6.[Abstract][Full Text]
49. Perrin EC, Sheldrick RC, McMenamy JM, et al. Improving parenting skills for families of young children in pediatric settings: a randomized clinical trial. JAMA Pediatr. 2014 Jan;168(1):16-24.[Abstract]
50. Sanders MR, Kirby JN, Tellegen CL, et al. The triple P-positive parenting program: a systematic review and meta-analysis of a multi-level system of parenting support. Clin Psychol Rev. 2014 Jun;34(4):337-57.[Abstract]
51. Chadi N, Walker-Harding L, Committee On Substance Use And Prevention. Nonmedical use of controlled medications by adolescents and young adults: clinical report. Pediatrics. 2024 Dec 1;154(6):e2024069298.[Abstract][Full Text]
52. Mullen JM, Richards JR, Crawford AT. Amphetamine related psychiatric disorders. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.[Abstract][Full Text]
53. Brecht ML, Herbeck D. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug Alcohol Depend. 2014 Jun 1;139:18-25.[Abstract][Full Text]
54. Yimsaard P, Maes MM, Verachai V, et al. Pattern of methamphetamine use and the time lag to methamphetamine dependence. J Addict Med. 2018 Mar/Apr;12(2):92-8.[Abstract][Full Text]
55. Chen LY, Strain EC, Alexandre PK, et al. Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. Addict Behav. 2014 May;39(5):829-36.[Abstract][Full Text]
56. Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018 Dec 1;193:14-20.[Abstract]
57. Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc. 2006 Jan;81(1):77-84.[Abstract]
58. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006 Aug;26(8):1148-56.[Abstract]
59. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila). 2010 Aug;48(7):675-94.[Abstract]
60. Department of Health and Social Care (UK). Drug misuse and dependence: UK guidelines on clinical management. Dec 2017 [internet publication].[Full Text]
61. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014 Dec;28(12):1115-26.[Abstract][Full Text]
62. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007 Feb;120(2):165-71.[Abstract]
63. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec;130(6):1657-63.[Abstract]
64. Goodchild JH, Donaldson M. Methamphetamine abuse and dentistry: a review of the literature and presentation of a clinical case. Quintessence Int. 2007 Jul-Aug;38(7):583-90.[Abstract]
65. Hargraves D, White C, Frederick R, et al. Implementing SBIRT (Screening, Brief Intervention and Referral to Treatment) in primary care: lessons learned from a multi-practice evaluation portfolio. Public Health Rev. 2017;38:31.[Abstract][Full Text]
66. American College of Surgeons. Best practices guidelines: screening and intervention for mental health disorders and substance use and misuse in the acute trauma patient. Dec 2022 [internet publication].[Full Text]
67. US Preventive Services Task Force. Final recommendation statement. Unhealthy drug use: screening. Jun 2020 [internet publication].[Full Text]
68. Levy SJ, Williams JF; Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016 Jul;138(1):e20161211.[Abstract][Full Text]
69. National Institute for Health and Care Excellence. Postnatal care. Apr 2021 [internet publication].[Full Text]
70. McKay JR. Impact of continuing care on recovery from substance use disorder. Alcohol Res. 2021 Jan 21;41(1):01.[Abstract][Full Text]
71. Iturralde E, Weisner CM, Adams SR, et al. Patterns of health care use 5 years after an intervention linking patients in addiction treatment with a primary care practitioner. JAMA Netw Open. 2022 Nov 1;5(11):e2241338.[Abstract][Full Text]
72. Minozzi S, Saulle R, Amato L, et al. Psychosocial interventions for stimulant use disorder. Cochrane Database Syst Rev. 2024 Feb 15;2(2):CD011866.[Abstract][Full Text]
73. US Department of Veterans Affairs. VA/DoD clinical practice guidelines: management of substance use disorder (SUD). Aug 2021 [internet publication].[Full Text]
74. United Nations Office on Drugs and Crime. UNODC treatment of stimulant use disorders: current practices and promising perspectives. May 2019 [internet publication].[Full Text]
75. American Society of Addiction Medicine. Engagement and retention of nonabstinent patients in substance use treatment: clinical consideration for addiction treatment providers. Oct 2024 [internet publication].[Full Text]
76. McGovern R, Newham JJ, Addison MT, et al. Effectiveness of psychosocial interventions for reducing parental substance misuse. Cochrane Database Syst Rev. 2021 Mar 16;3(3):CD012823.[Abstract][Full Text]
77. Stuart AM, Baker AL, Denham AMJ, et al. Psychological treatment for methamphetamine use and associated psychiatric symptom outcomes: a systematic review. J Subst Abuse Treat. 2020 Feb;109:61-79.[Abstract][Full Text]
78. De Crescenzo F, Ciabattini M, D'Alò GL, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. PLoS Med. 2018 Dec;15(12):e1002715.[Abstract][Full Text]
79. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006 Feb;101(2):267-74.[Abstract]
80. Brown HD, DeFulio A. Contingency management for the treatment of methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020 Nov 1;216:108307.[Abstract]
81. Ronsley C, Nolan S, Knight R, et al. Treatment of stimulant use disorder: a systematic review of reviews. PLoS One. 2020;15(6):e0234809.[Abstract][Full Text]
82. Rawson R, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002 Sep;23(2):145-50.[Abstract]
83. Roll JM, Petry NM, Stitzer ML, et al. Contingency for the treatment of methamphetamine use disorder. Am J Psychiatry. 2006 Nov;163(11):1993-9.[Abstract]
84. Bentzley BS, Han SS, Neuner S, et al. Comparison of treatments for cocaine use disorder among adults: a systematic review and meta-analysis. JAMA Netw Open. 2021 May 3;4(5):e218049.[Abstract][Full Text]
85. Higgins ST, Budney AJ, Bickel WK, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994 Jul;51(7):568-76.[Abstract]
86. Rawson RA, Huber A, McCann M, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry. 2002 Sep;59(9):817-24.[Abstract][Full Text]
87. Prendergast M, Podus D, Finney J, et al. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006 Nov;101(11):1546-60.[Abstract]
88. Colfax G, Santos GM, Chu P, et al. Amphetamine-group substances and HIV. Lancet. 2010 Aug 7;376(9739):458-74.[Abstract]
89. McPherson SM, Burduli E, Smith CL, et al. A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies. Subst Abuse Rehabil. 2018;9:43-57.[Abstract][Full Text]
90. Kurti AN, Davis DR, Redner R, et al. A review of the literature on remote monitoring technology in incentive-based interventions for health-related behavior change. Transl Issues Psychol Sci. 2016 Jun;2(2):128-52.[Abstract][Full Text]
91. Harada T, Tsutomi H, Mori R, et al. Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders. Cochrane Database Syst Rev. 2018 Dec 22;(12):CD011315.[Abstract][Full Text]
92. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008 Feb;165(2):179-87.[Abstract][Full Text]
93. Maude-Griffin PM, Hohenstein JM, Humfleet GL, et al. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998 Oct;66(5):832-7.[Abstract]
94. Rohsenow DJ, Monti PM, Martin RA, et al. Brief coping skills treatment for cocaine abuse: 12-month substance use outcomes. J Consult Clin Psychol. 2000 Jun;68(3):515-20.[Abstract]
95. Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994 Mar;51(3):177-87.[Abstract]
96. Schwenker R, Dietrich CE, Hirpa S, et al. Motivational interviewing for substance use reduction. Cochrane Database Syst Rev. 2023 Dec 12;12(12):CD008063.[Abstract]
97. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005 May 9;78(2):125-34.[Abstract]
98. AshaRani PV, Hombali A, Seow E, et al. Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020 Jul 1;212:108060.[Abstract][Full Text]
99. Amiri Z, Mirzaee B, Sabet M. Evaluating the efficacy of regulated 12-session Matrix Model in reducing susceptibility in methamphetamine-dependent individuals. Int J Med Res Health Sci. 2016;5(2):77-85.[Full Text]
100. De Giorgi R, Cassar C, Loreto D'alò G, et al. Psychosocial interventions in stimulant use disorders: a systematic review and qualitative synthesis of randomized controlled trials. Riv Psichiatr. 2018 Sep-Oct;53(5):233-55.[Abstract][Full Text]
101. McLellan AT, Hagan TA, Meyers K, et al. "Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment. J Addict Dis. 1997;16(2):57-84.[Abstract]
102. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry. 2009 May;22(3):263-8.[Abstract][Full Text]
103. Wouldes T, LaGasse L, Sheridan J, et al. Maternal methamphetamine use during pregnancy and child outcome: what do we know? N Z Med J. 2004 Nov 26;117(1206):U1180.[Abstract]
104. Eze N, Smith LM, LaGasse LL, et al. School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the Infant Development, Environment, and Lifestyle Study. J Pediatr. 2016 Mar;170:34-8.e1.[Abstract][Full Text]
105. World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].[Full Text]
106. Washio Y, Atreyapurapu S, Hayashi Y, et al. Systematic review on use of health incentives in U.S. to change maternal health behavior. Prev Med. 2021 Apr;145:106442.[Abstract]
107. Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020 Apr;34(4):337-65.[Abstract][Full Text]
108. Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. Expert Opin Pharmacother. 2019 Dec;20(18):2273-93.[Abstract]
109. Lee NK, Jenner L, Harney A, et al. Pharmacotherapy for amphetamine dependence: a systematic review. Drug Alcohol Depend. 2018 Oct 1;191:309-37.[Abstract]
110. Chan B, Freeman M, Kondo K, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder - a systematic review and meta-analysis. Addiction. 2019 Dec;114(12):2122-36.[Abstract]
111. Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009 Feb;104(2):224-33.[Abstract]
112. Longo M, Wickes W, Smout M, et al. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010 Jan;105(1):146-54.[Abstract]
113. Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014 Sep;109(9):1489-500.[Abstract][Full Text]
114. Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Jul;108(7):1279-86.[Abstract]
115. Solhi H, Jamilian HR, Kazemifar AM, et al. Methylphenidate vs. resperidone in treatment of methamphetamine dependence: a clinical trial. Saudi Pharm J. 2014 Jul;22(3):191-4.[Abstract][Full Text]
116. Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015 Sep;40(10):2347-56.[Abstract][Full Text]
117. Comer SD, Mogali S, Saccone PA, et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology. 2013 Nov;38(12):2427-38.[Abstract][Full Text]
118. Stoops WW, Rush CR. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Expert Rev Clin Pharmacol. 2014 May;7(3):363-74.[Abstract][Full Text]
119. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021 Jan 14;384(2):140-53.[Abstract][Full Text]
120. De La Garza R 2nd, Newton TF, Haile CN, et al. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):141-6.[Abstract]
121. Chang CH, Liou MF, Liu CY, et al. Efficacy of repetitive transcranial magnetic stimulation in patients with methamphetamine use disorder: a systematic review and meta-analysis of double-blind randomized controlled trials. Front Psychiatry. 2022 May 27;13:904252.[Abstract][Full Text]
122. Makani R, Pradhan B, Shah U, et al. Role of repetitive transcranial magnetic stimulation (rTMS) in treatment of addiction and related disorders: a systematic review. Curr Drug Abuse Rev. 2017;10(1):31-43.[Abstract]
123. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005 Oct;108(1):76-85.[Abstract]
124. Collins KC, Schlosburg JE, Bremer PT, et al. Methamphetamine vaccines: improvement through hapten design. J Med Chem. 2016 Apr 28;59(8):3878-85.[Abstract][Full Text]
125. Farahzadi MH, Moazen-Zadeh E, Razaghi E, et al. Riluzole for treatment of men with methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2019 Mar;33(3):305-15.[Abstract]
126. Goldberg SB, Pace B, Griskaitis M, et al. Mindfulness-based interventions for substance use disorders. Cochrane Database Syst Rev. 2021 Oct 20;(10):CD011723.[Abstract][Full Text]
127. Maneesang W, Hengpraprom S, Kalayasiri R. Effectiveness of mindfulness-based therapy and counseling programs (MBTC) on relapses to methamphetamine dependence at a substance dependency treatment center. Psychiatry Res. 2022 Nov;317:114886.[Abstract]
128. Rostami R, Dehghani-Arani F. Neurofeedback training as a new method in treatment of crystal methamphetamine dependent patients: a preliminary study. Appl Psychophysiol Biofeedback. 2015 Sep;40(3):151-61.[Abstract]
129. Crowley R, Kirschner N, Dunn AS, et al. Health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs: an American College of Physicians position paper. Ann Intern Med. 2017 May 16;166(10):733-6.[Abstract][Full Text]
130. Calabria BD, Degenhardt L, Briegleb C, et al. Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav. 2010 Aug;35(8):741-9.[Abstract]
131. Turnipseed SD, Richards JR, Kirk D, et al. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003 May;24(4):369-73.[Abstract]
132. Mortelmans LJM, Bogaerts PJM, Hellemans S, et al. Spontaneous pneumomediastinum and myocarditis following ecstasy use: a case report. Eur J Emerg Med. 2005 Feb;12(1):36-8.[Abstract]
133. Dickson SD, Thomas IC, Bhatia HS, et al. Methamphetamine-associated heart failure hospitalizations across the United States: geographic and social disparities. J Am Heart Assoc. 2021 Aug 17;10(16):e018370.[Abstract][Full Text]
134. Swalwell CI, Davis GG. Methamphetamine as a risk factor for acute aortic dissection. J Forensic Sci. 1999 Jan;44(1):23-6.[Abstract]
135. Rejali D, Glen P, Odom N. Pneumomediastinum following ecstasy (methylenedioxymethamphetamine, MDMA) ingestion in two people at the same "rave". J Laryngol Otol. 2002 Jan;116(1):75-6.[Abstract]
136. National Toxicology Program. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. NTP CERHR MON. 2005 Jul;(16):i-III-1.[Abstract][Full Text]
137. Tucker P. Substance misuse and early psychosis. Australas Psychiatry. 2009 Aug;17(4):291-4.[Abstract]
138. Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health. 2006 Nov;83(6):1151-7.[Abstract][Full Text]
139. Silber BY, Croft RJ, Papafotiou K, et al. The effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology (Berl). 2006 Aug;187(2):154-69.[Abstract]
140. Sheridan J, Bennett S, Coggan C, et al. Injury with methamphetamine use: a review of the literature. Harm Reduct J. 2006 Mar 29;3:14.[Abstract][Full Text]
141. Fischer B, Haydon E, Rehm J, et al. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach - the case study of Canada. J Urban Health. 2004 Sep;81(3):428-47.[Abstract][Full Text]
142. Centers for Disease Control and Prevention. Vaccines and immunizations: adult immunization schedule by age: recommendations for ages 19 years or older, United States, 2025. Nov 2024 [internet publication].[Full Text]
143. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. 2021 [internet publication].[Full Text]
